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Summary
Observationally, higher caffeine consumption is associated with poorer sleep and
insomnia. We investigated whether these associations are a result of shared genetic
risk factors and/or (possibly bidirectional) causal effects. Summary-level data were
available from genome-wide association studies on caffeine intake (n = 91 462),
plasma caffeine and caffeine metabolic rate (n = 9876), sleep duration and chrono-
type (being a “morning” versus an “evening” person) (n = 128 266), and insomnia
complaints (n = 113 006). First, genetic correlations were calculated, reflecting the
extent to which genetic variants influencing caffeine consumption and those influ-
encing sleep overlap. Next, causal effects were estimated with bidirectional, two-
sample Mendelian randomization. This approach utilizes the genetic variants most
robustly associated with an exposure variable as an “instrument” to test causal
effects. Estimates from individual variants were combined using inverse-variance
weighted meta-analysis, weighted median regression and MR-Egger regression. We
found no clear evidence for a genetic correlation between caffeine intake and sleep
duration (rg = 0.000, p = .998), chronotype (rg = 0.086, p = .192) or insomnia com-
plaints (rg = 0.034, p = .700). For plasma caffeine and caffeine metabolic rate,
genetic correlations could not be calculated because of the small sample size. Men-
delian randomization did not support causal effects of caffeine intake on sleep, or
vice versa. There was weak evidence that higher plasma caffeine levels causally
decrease the odds of being a morning person. Although caffeine may acutely affect
sleep when taken shortly before bedtime, our findings suggest that a sustained pat-
tern of high caffeine consumption is more likely to be associated with poorer sleep
through shared environmental factors. Future research should identify such environ-
ments, which could aid the development of interventions to improve sleep.
K E YWORD S
1,3,7-Trimethylxanthine, genetic overlap, duration of sleep, ‘morningness’, instrumental variable
analysis, sleeplessness
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1 | INTRODUCTION
Caffeine is the most commonly used psychoactive substance, with
coffee being the second most popular beverage worldwide (after
water) (Butt & Sultan, 2011). There are also cultural differences in
the popularity of caffeinated beverages, with tea being more popular
than coffee in some countries, such as the UK (Treur et al., 2016).
Acutely, caffeine is known to affect alertness and concentration
through its antagonistic effects on adenosine receptors (Griffiths
et al., 1990; Porkka-Heiskanen & Kalinchuk, 2011), although because
of tolerance the net benefit of frequent caffeine consumption
appears to be negligible (Rogers, Heatherley, Mullings, & Smith,
2013). Consumption of caffeinated beverages has also been linked
to poor sleep. A recent review of the literature showed that an aver-
age higher caffeine consumption is associated with prolonged sleep
latency (the time it takes to fall asleep), reduced sleep time, reduced
sleep efficiency (percentage of time asleep of the total time in bed)
and poorer sleep quality (Clark & Landolt, 2017). Moreover, caffeine
consumption correlates positively with insomnia complaints (Chaud-
hary, Grandner, Jackson, & Chakravorty, 2016; Skarupke et al.,
2017) and negatively with chronotype (being a “morning” versus an
“evening” person) (Fabbian et al., 2016; Suh et al., 2017). Given the
higher mortality rates and poorer health outcomes associated with
sleep problems (Itani, Jike, Watanabe, & Kaneita, 2017; Tang, Fiecas,
Afolalu, & Wolke, 2017), it is important to understand how caffeine
consumption relates to different sleep behaviours.
The co-occurrence of high caffeine consumption and poor sleep
may be the result of different (not mutually exclusive) mechanisms.
First, factors that increase the amount of caffeine a person con-
sumes may also increase their risk of having problems with sleeping.
Such overlapping risk factors could be environmental in nature or
genetic. From twin-family studies, we know that caffeine consump-
tion as well as sleep behaviours are heritable. Individual differences
in caffeine consumption were explained by genetic factors for ~50%
(Treur et al., 2017), whereas this was ~39% for sleep duration (Wat-
son et al., 2016), ~42% for chronotype (Toomey, Panizzon, Kremen,
Franz, & Lyons, 2015) and ~59% in women and ~38% in men for
insomnia (Lind, Aggen, Kirkpatrick, Kendler, & Amstadter, 2015).
More recently, large-scale genome-wide association (GWA) studies
have identified specific genetic variants associated with each of
these traits (Cornelis et al., 2015; Hammerschlag et al., 2017; Jones
et al., 2016). Apart from overlapping (genetic) risk factors, the associ-
ation between caffeine consumption and sleep may also be
explained by causal effects. Given the well-known stimulating effects
of caffeine, it seems plausible that a sustained, high intake of caf-
feine can cause problems with sleeping. In extreme cases, it may
even cause or exacerbate symptoms of insomnia. Controlled labora-
tory studies suggest that caffeine negatively impacts human sleep
quality (Clark & Landolt, 2017). In these studies, however, caffeine
was typically administered shortly before habitual bedtime (i.e.
≤60 min before), which may not reflect real-life consumption pat-
terns. In addition, most of these studies have been conducted in
male participants only. More importantly, laboratory studies do not
provide insight into the effects of prolonged high(er) intake of caf-
feine and causal effects in the other direction have not been tested:
individuals who tend to sleep less and/or have insomnia may con-
sume more caffeine to alleviate the effects of sleep deprivation dur-
ing the day (Clark & Landolt, 2017; Penetar et al., 1993). Novel
methods are needed to fully disentangle the complex relationship
between caffeine consumption and sleep, focusing especially on pos-
sible longer-term causal effects.
To determine whether observational associations between caf-
feine consumption and sleep variables are a result of overlapping
genetic risk factors and/or causal effects (in either direction), we
applied two methods. First, we calculated genetic correlations
between caffeine consumption and sleep duration, insomnia com-
plaints and chronotype based on summary level data of recent GWA
studies (Cornelis et al., 2015, 2016; Hammerschlag et al., 2017;
Jones et al., 2016). These genetic correlations reflect the extent to
which genetic variants that are known to influence caffeine con-
sumption also influence sleep behaviours (Bulik-Sullivan et al., 2015).
Evidence of genetic correlation indicates shared genetic aetiologies
but may also (partly) reflect causal effects. If caffeine consumption
causally affects sleep, one would expect that genetic variants that
predict caffeine consumption, also predict sleep. To further investi-
gate the possibility of such causal effects, and their direction, we
applied two-sample Mendelian randomization (MR) analysis. This
instrumental variable approach utilizes a selection of genetic variants
that are robustly associated with an exposure variable as an instru-
ment to test causal effects on an outcome variable (Burgess, Scott,
Timpson, Davey Smith, & Thompson, 2015; Davey Smith & Ebrahim,
2003). We examined potential biological pleiotropy (i.e.. effects of
genotype on the outcome of interest not acting through the expo-
sure) with two sensitivity analyses. By combining two novel research
methods we aim to disentangle mechanisms underlying observational
associations between caffeine consumption and sleep behaviours.
2 | METHODS
2.1 | Study population
To capture caffeine consumption, we used summary statistics from
two different GWA studies. The first study was the Coffee and Caf-
feine Genetics Consortium GWA study (n = 91 462) (Cornelis et al.,
2015), which investigated caffeine intake. The outcome of this study
was cups of coffee per day, but genetic risk scores composed of the
top genetic hits have been shown to be associated more generally
with the intake of other types of caffeinated beverages (e.g. tea) as
well (Taylor, Davey Smith, & Munafo, 2018). The second study was
a GWA study that looked at plasma caffeine and its main metabo-
lites as measured in the blood (n = 9876) (Cornelis et al., 2016). The
most informative outcomes of this GWA study were total plasma
caffeine and the paraxanthine/plasma caffeine ratio, which reflects
caffeine metabolic rate. Paraxanthine is the main metabolite of
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caffeine, with a higher ratio indicating a faster caffeine metabolism
(Cornelis et al., 2016).
For sleep behaviours, GWA studies’ summary statistics were
available for sleep duration, in hours of sleep and chronotype (a con-
tinuous score of being a “morning” versus an “evening” person) (both
n = 128 266) (Jones et al., 2016), and for insomnia complaints (usu-
ally having trouble falling asleep at night or waking up in the middle
of the night [“cases”] versus never/rarely or sometimes having these
problems [“controls”]) (n = 113 006) (Hammerschlag et al., 2017).
The GWA studies on sleep behaviours were performed using UK
Biobank (Sudlow et al., 2015) and there was no sample overlap with
the GWA studies on caffeine consumption.
2.2 | LD score regression
To calculate genetic correlations between caffeine consumption and
sleep behaviours, we employed LD score regression. Linkage disequi-
librium (LD) is the degree to which genetic variants (single nucleotide
polymorphisms [SNPs]) are transmitted together from parent to off-
spring. The main premise of LD score regression is that genetic vari-
ants that are in high LD with other genetic variants across the
genome, are more likely to tag a causal genetic variant (one that
exerts a true, causal effect on the phenotype in question) than
genetic variants that are in low LD with other genetic variants.
Based on this expected relationship between LD and the strength of
association, for two phenotypes, a genetic correlation can be calcu-
lated. The genetic correlation reflects to what degree the genetic
liability for one phenotype correlates with the genetic liability for a
second phenotype. LD score regression methods have been
described in more detail previously (Bulik-Sullivan et al., 2015). We
calculated genetic correlations using the summary data described
above. Pre-calculated and publicly available LD scores (the degree
of LD an SNP has with all neighbouring SNPs) based on individuals
of European ancestry were retrieved from https://github.com/bu
lik/ldsc.
2.3 | Mendelian randomization
Mendelian randomization (MR) uses genetic variants that are
robustly associated with an exposure variable as an instrument to
test causal effects on an outcome variable (Davey Smith & Ebrahim,
2003). With conventional epidemiological methods, it is difficult to
determine causality because an observational association can also be
the result of confounding factors that predict both variables (e.g.
socio-economic position) or reverse causality (an outcome variable
affecting the exposure variable). MR is in principle better protected
against confounding than conventional epidemiological methods
because genetic variants are randomly transmitted in the population.
Additionally, reverse causality cannot affect MR results because an
outcome variable cannot change a person’s genotype. There are
three important assumptions underlying MR: (i) the genetic instru-
ment should be robustly associated with the exposure variable, (ii)
the genetic instrument should be independent of confounders, and
(iii) there should be no biological (or horizontal) pleiotropy, meaning
that the genetic instrument should not affect the outcome variable
through an independent pathway, other than through its effect on
the exposure variable.
Here, we applied two-sample MR, in which a genetic instrument
is first identified in a GWA study of the exposure variable (gene–ex-
posure association) and then the same instrument is identified in a
second, separate GWA study of the outcome variable (gene–outcome
association) (Burgess et al., 2015). When the genetic instrument was
composed of a single genetic variant the Wald ratio method was
applied (gene–outcome association/gene–exposure association) (Law-
lor, Harbord, Sterne, Timpson, & Davey Smith, 2008). When the
instrument comprised multiple genetic variants, Wald ratios were
combined in an inverse-variance weighted (IVW) meta-analysis (sum-
ming ratio estimates of all variants in a weighted average formula)
(Lawlor et al., 2008). To test the third MR assumption (no horizontal
pleiotropy) we additionally used two sensitivity analyses. First, we
used the weighted median approach, which is a method that can
provide a consistent estimate of a causal effect even in a situation
where up to 50% of the weight comes from invalid instruments
(Bowden, Davey Smith, Haycock, & Burgess, 2016). Second, we used
MR-Egger regression, which applies Egger’s test, normally used to
assess small study bias in meta-analyses, to genetic instruments with
multiple genetic variants (Bowden, Davey Smith, & Burgess, 2015).
Under MR-Egger it is assumed that there is no correlation between
the strength of an instrument (SNP–exposure association) and the
effect that the instrument has on the outcome. This is referred to as
the InSIDE assumption (instrument strength independent of direct
effect) and it is a much weaker assumption than the assumption of
no horizontal pleiotropy. MR-Egger was only reported for genetic
instruments that contained sufficient SNPs (≥10) (Bowden et al.,
2015).
Genetic instruments were first identified for caffeine (caffeine
intake, plasma caffeine and caffeine metabolic rate), after which cau-
sal effects on sleep behaviours (sleep duration, chronotype and
insomnia complaints) were tested. Next, genetic instruments for the
different sleep behaviours were identified and causal effects on caf-
feine were tested. For each phenotype, we constructed two genetic
instruments: one consisting of SNPs that were associated with the
exposure variable under the genome-wide significant p-value thresh-
old of p < 5 9 108 and one consisting of SNPs associated with the
exposure variable under a more lenient p-value threshold of
p < 1 9 105. All analyses were performed using the database and
analytical platform MR-Base (Hemani et al., 2016). For instruments of
threshold p < 5 9 108, all independent genome-wide significant
hits were selected manually from the published GWA study papers
(based on the discovery samples) and then introduced to MR-Base,
whereas instruments of threshold p < 1 9 105 were constructed in
MR-Base (including the pruning of genetic variants [r2 < 0.001] and
retrieving of proxies [r2 ≥ 0.8]). Details of the SNPs included in all
genetic instruments are provided in Table S1. Associations of SNPs
with plasma caffeine and caffeine metabolic rate were only available
as z-scores, so we constructed beta coefficients and standard errors
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from the z-scores, effect allele frequencies and sample size (see
Tables 2 and 3 for the formula) (Taylor et al., 2016).
3 | RESULTS
With LD score regression, we found no clear evidence for a genetic
correlation between caffeine intake and sleep duration (rg = 0.000,
standard error [SE] = 0.079, p = .998), caffeine intake and chrono-
type (rg = 0.086, SE = 0.066, p = .192), or caffeine intake and insom-
nia complaints (rg = 0.034, SE = 0.087, p = .700). Thus, across the
whole genome, genetic variants that influence caffeine intake don’t
seem to be predictive of sleep behaviours. We were unable to calcu-
late genetic correlations between plasma caffeine and caffeine meta-
bolic rate and sleep behaviours, because of the modest sample size
of the GWA studies these summary statistics were based on.
Two-sample MR, using all three analytical approaches, did not
provide clear evidence for causal effects of caffeine intake on sleep
duration, chronotype or insomnia complaints, or vice versa. More
details are provided in Table 1. Cochran’s heterogeneity statistic (Q),
which assesses heterogeneity between the different SNPs included
in a genetic instrument, indicated heterogeneity for IVW analyses
from caffeine intake to chronotype (see Table S2). The intercepts
from MR-Egger regression analyses, which estimate the degree of
biological pleiotropy, did not provide strong evidence for pleiotropy
overall, although there was some weak evidence for pleiotropy from
chronotype to caffeine intake (see Table S3).
There was weak evidence that higher plasma caffeine levels
decrease the odds of being a morning person (Wald ratio
beta = 0.05, p = .045, and IVW beta = 0.03, p = .012, for genetic
instruments with threshold p < 5 9 108 and p < 1 9 105, respec-
tively; Table 2). The two sensitivity analyses indicated similar effect
sizes in the same direction, albeit with weaker statistical evidence.
There was also some weak evidence that insomnia complaints
increase plasma caffeine, but only for the (one-SNP) genetic instru-
ment with threshold p < 5 9 108 (Wald ratio beta = 0.47,
p = .097). There was no clear evidence for other causal effects
between plasma caffeine and sleep behaviours, nor was there evi-
dence for heterogeneity between the different SNPs or biological
pleiotropy (see Tables S4 and S5).
TABLE 1 Bidirectional, two-sample Mendelian randomization analyses between caffeine intake and sleep behaviours
Exposure Outcome
Threshold genetic
instrument
n
SNPs
Wald ratio/IVW Weighted median MR-Egger
beta OR SE p beta OR SE p beta OR SE p
Caffeine
intake
Sleep
duration
p < 5 9 108 4 0.02 0.02 .337 0.02 0.02 .492
Caffeine
intake
Sleep
duration
p < 1 9 105 27 0.00 0.02 .796 0.01 0.02 .771 0.01 0.03 .694
Caffeine
intake
Chronotype p < 5 9 108 4 0.03 0.03 .405 0.03 0.03 .228
Caffeine
intake
Chronotype p < 1 9 105 27 0.01 0.02 .743 0.00 0.02 .951 0.04 0.03 .207
Caffeine
intake
Insomnia p < 5 9 108 4 0.01 0.99 0.05 .856 0.00 1.00 0.05 .957
Caffeine
intake
Insomnia p < 1 9 105 27 0.04 0.96 0.03 .168 0.01 0.99 0.05 .890 0.02 0.98 0.06 .712
Sleep
duration
Caffeine
intake
p < 5 9 108 3 0.12 0.17 .457 0.14 0.19 .464
Sleep
duration
Caffeine
intake
p < 1 9 105 23 0.15 0.10 .135 0.00 0.12 .987 0.41 0.37 .285
Chronotype Caffeine
intake
p < 5 9 108 8 0.01 0.12 .904 0.11 0.15 .483
Chronotype Caffeine
intake
p < 1 9 105 55 0.09 0.06 .096 0.13 0.08 .092 0.36 0.22 .113
Insomnia Caffeine
intake
p < 5 9 108 1 0.07 0.13 .628
Insomnia Caffeine
intake
p < 1 9 105 16 0.06 0.05 .194 0.04 0.06 .515 0.12 0.19 .554
In the case of a genetic instrument consisting of a single nucleotide polymorphism (SNP) the Wald ratio is reported, otherwise IVW (inverse-variance
weighted regression analysis) is reported. Weighted median regression analysis is only reported for genetic instruments consisting of ≥3 SNPs. MR-Egger
regression analysis is only reported for genetic instruments consisting of ≥10 SNPs. Definitions of the exposure and outcome variables in the genome-
wide association (GWA) studies were: caffeine intake (cups of coffee per day), sleep duration (hours of sleep), chronotype (a continuous score of being
a ‘morning’ versus an ‘evening’ person) and insomnia (usually having trouble falling asleep at night or waking up in the middle of the night [‘cases’] ver-
sus never/rarely or sometimes having these problems [‘controls’]).
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There was weak evidence that a higher caffeine metabolic rate
decreased sleep duration, but only for the genetic instrument with
threshold p < 1 9 105 (IVW beta = 0.02, p = 0.045; Table 3).
There was also some indication that a higher caffeine metabolic rate
increases the odds of being a morning person, but only for the (one-
SNP) genetic instrument with threshold p < 5 9 108 (Wald ratio
beta = 0.04, p = .045). Finally, there was some weak evidence that a
higher caffeine metabolic rate increases insomnia complaints, but only
for the genetic instrument with threshold p < 1 9 105 (IVW
beta = 0.04, p = .057). There was no clear evidence for heterogeneity
between SNPs, nor for biological pleiotropy (see Tables S6 and S7).
4 | DISCUSSION
We did not find clear evidence in support of a genetic correlation
between caffeine intake on the one hand and sleep duration,
insomnia complaints or chronotype on the other hand. Apart from a
few suggestive findings, which were further weakened as a result of
the multiple testing burden, our results from Mendelian randomiza-
tion analyses also did not support causal relationships from caffeine
intake, plasma caffeine and caffeine metabolic rate to sleep beha-
viours, or the other way around. These results suggest that a longer-
term, average pattern of high caffeine consumption is associated
with poorer sleep through shared environmental factors.
Our findings corroborate previous reports showing that none of
the genetic variants associated with caffeine intake were associated
with caffeine-induced insomnia (Byrne et al., 2012; Cornelis et al.,
2015). This might seem to contradict controlled laboratory studies
that suggest that caffeine has a causal, negative impact on sleep
(Clark & Landolt, 2017). However, in most of these studies, partici-
pants were administered caffeine immediately before their usual
bedtime, and so acute, short-term effects of caffeine were tested. In
the current study, we measured genetic liability for caffeine intake, a
TABLE 2 Bidirectional, two-sample Mendelian randomization analyses between plasma caffeine and sleep behaviours
Exposure Outcome
Threshold genetic
instrument
n
SNPs
Wald ratio/IVW Weighted median MR-Egger
beta OR SE p beta OR SE p beta OR SE p
Plasma
caffeine
Sleep
duration
p < 5 9 108 1 0.03 0.03 .285
Plasma
caffeine
Sleep
duration
p < 1 9 105 11 0.01 0.01 .662 0.02 0.02 .355 0.04 0.04 .367
Plasma
caffeine
Chronotype p < 5 9 108 1 0.05 0.03 .045
Plasma
caffeine
Chronotype p < 1 9 105 11 0.03 0.01 .012 0.03 0.02 .074 0.05 0.05 .334
Plasma
caffeine
Insomnia p < 5 9 108 1 0.02 1.02 0.06 .770
Plasma
caffeine
Insomnia p < 1 9 105 11 0.01 1.01 0.07 .340 0.02 1.02 0.04 .630 0.07 1.07 0.11 .556
Sleep
duration
Plasma
caffeine
p < 5 9 108 2 0.25 0.54 .650
Sleep
duration
Plasma
caffeine
p < 1 9 105 16 0.34 0.27 .204 0.33 0.36 .355 0.71 1.08 .517
Chronotype Plasma
caffeine
p < 5 9 108 4 0.05 0.49 .919 0.08 0.57 .886
Chronotype Plasma
caffeine
p < 1 9 105 42 0.22 0.17 .198 0.38 0.24 .113 0.16 0.75 .834
Insomnia Plasma
caffeine
p < 5 9 108 1 0.47 0.28 .097
Insomnia Plasma
caffeine
p < 1 9 105 14 0.07 0.13 .601 0.20 0.18 .248 0.32 0.52 .547
In the case of a genetic instrument consisting of a single nucleotide polymorphisms (SNP) the Wald ratio is reported, otherwise IVW (inverse-variance
weighted regression analysis) is reported. Weighted median regression analysis is only reported for genetic instruments consisting of ≥3 SNPs. MR-Egger
regression analysis is only reported for genetic instruments consisting of ≥10 SNPs. Definitions of the exposure and outcome variables in the genome-
wide association (GWA) studies were: plasma caffeine (caffeine levels as measured in blood plasma), sleep duration (hours of sleep), chronotype (a con-
tinuous score of being a ‘morning’ versus an ‘evening’ person) and insomnia (usually having trouble falling asleep at night or waking up in the middle of
the night [‘cases’] versus never/rarely or sometimes having these problems [‘controls’]). For plasma caffeine, constructed beta values were calculated as
Beta = z-score/sqrt(N) * 1/SQRT(EAF(1-EAF)). This calculation assumes that the standard errors are proportional to the inverse-square root of the sam-
ple size multiplied by the variance of the genetic variant as a random variable (variance = EAF(1-EAF)). This result should hold asymptotically.
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measure that reflects a more sustained life-time average intake of
caffeine, and not only intake just before going to sleep. It may be
the case that caffeine impacts sleep when it is consumed in the eve-
ning, whereas there is little or no effect when it is consumed during
the day. It is likely that most caffeine is consumed earlier during the
day, given that a common reason for consuming caffeinated bever-
ages is their stimulant effects (Ludden, O’Brien, & Pasch, 2017;
Reich, Dietrich, Reid Finlayson, Fischer, & Martin, 2008). One small
study (n = 12) looked at the effects of a high dose of caffeine
(400 mg, similar to the amount of caffeine in at least four cups of
coffee) on sleep when administered 0, 3 or 6 hr before bedtime and
did find disruptive effects on sleep at all time-points (Drake, Roehrs,
Shambroom, & Roth, 2013). Another possibility for the lack of evi-
dence for causal effects in the present study is that, over time, toler-
ance of the effects of caffeine develops (Rogers et al., 2013), which
would mean that frequent consumption of caffeine doesn’t disrupt
sleep. In fact, caffeine withdrawal has previously been found to
increase sleepiness, at least for daytime sleepiness (Rogers et al.,
2013).
The most compelling of our suggestive causal findings was a neg-
ative effect of plasma caffeine levels on chronotype, decreasing the
odds of being a morning person. This might indicate that people with
higher circulating levels of caffeine stay up later and consequently
find it harder to get up early in the morning. This is consistent with
TABLE 3 Bidirectional, two-sample Mendelian randomization analyses between caffeine metabolic rate and sleep behaviours
Exposure Outcome
Threshold
genetic
instrument
n
SNPs
Wald ratio/IVW Weighted median MR-Egger
beta OR SE p beta OR SE p beta OR SE p
Caffeine
metabolic rate
Sleep
duration
p < 5 9 108 1 0.02 0.02 0.285
Caffeine
metabolic rate
Sleep
duration
p < 1 9 105 8 0.02 0.01 0.045 0.02 0.01 0.150
Caffeine
metabolic rate
Chronotype p < 5 9 108 1 0.04 0.02 0.045
Caffeine
metabolic rate
Chronotype p < 1 9 105 8 0.01 0.01 0.547 0.03 0.01 0.074
Caffeine
metabolic rate
Insomnia p < 5 9 108 2 0.01 1.01 0.03 0.709
Caffeine
metabolic rate
Insomnia p < 1 9 105 9 0.04 1.04 0.02 0.057 0.02 1.02 0.03 0.492
Sleep duration Caffeine
metabolic
rate
p < 5 9 108 2 0.04 0.70 0.953
Sleep duration Caffeine
metabolic
rate
p < 1 9 105 16 0.17 0.35 0.624 0.21 0.51 0.678 0.57 1.45 0.699
Chronotype Caffeine
metabolic
rate
p < 5 9 108 4 0.26 0.63 0.686 0.16 0.73 0.822
Chronotype Caffeine
metabolic
rate
p < 1 9 105 42 0.20 0.23 0.384 0.34 0.33 0.297 0.80 1.02 0.433
Insomnia Caffeine
metabolic
rate
p < 5 9 108 1 0.57 0.36 0.118
Insomnia Caffeine
metabolic
rate
p < 1 9 105 14 0.09 0.18 0.609 0.25 0.24 0.283 0.33 0.73 0.658
In the case of a genetic instrument consisting of a single nucleotide polymorphism (SNP) the Wald ratio is reported, otherwise IVW (inverse-variance
weighted regression analysis) is reported. Weighted median regression analysis is only reported for genetic instruments consisting of ≥3 SNPs. MR-Egger
regression analysis is only reported for genetic instruments consisting of ≥10 SNPs. Definitions of the exposure and outcome variables in the genome-
wide association (GWA) studies were: caffeine metabolic rate (paraxanthine/plasma caffeine ratio, paraxanthine being the main metabolite of caffeine
and the ratio reflecting an individual’s metabolic rate of caffeine), sleep duration (hours of sleep), chronotype (a continuous score of being a ‘morning’
versus an ‘evening’ person) and insomnia (usually having trouble falling asleep at night or waking up in the middle of the night [‘cases’] versus never/
rarely or sometimes having these problems [‘controls’]). For caffeine metabolic rate, constructed beta values were calculated as Beta = z-score/sqrt(N) *
1/SQRT(EAF(1-EAF)). This calculation assumes that the standard errors are proportional to the inverse-square root of the sample size multiplied by the
variance of the genetic variant as a random variable (variance = EAF(1-EAF)). This result should hold asymptotically.
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previous literature showing that being more of an evening person is
associated with consuming more coffee and other caffeinated bever-
ages (Fabbian et al., 2016; Suh et al., 2017). Caffeine levels mea-
sured in blood plasma should provide a more accurate measure of a
person’s exposure to the stimulating effects of caffeine because this
considers biological differences in caffeine metabolism. However,
our evidence was weak, and further research into this relationship is
warranted.
In contrast to previous (laboratory) studies, we were also able to
test causal effects in the direction from sleep behaviours to caffeine.
We did not find any clear evidence for causal effects. This is in con-
trast to research showing that a common reason for changing coffee
consumption is experiencing sleep problems (Soroko, Chang, & Bar-
rett-Connor, 1996). It may be that such causal effects did not
emerge in our analyses because these are only short-term adjust-
ments in caffeine use that do not hold in the longer term, whereas
our genetic approach reflects a longer-term measure of caffeine
consumption.
The lack of evidence for genetic correlation between caffeine
consumption and sleep behaviours, and for causal effects, suggests
that observational associations may be the result of shared environ-
mental factors. The literature on this topic is scarce, but an example
of an environmental factor that could be responsible for both
increasing caffeine consumption and inducing or exacerbating sleep-
ing problems is work or school-related demands and stress (Dorrian
et al., 2011; Zunhammer, Eichhammer, & Busch, 2014). Daily stress
may cause people to have trouble sleeping and may consequently
cause them to attempt to self-medicate by consuming more caffeine.
More research is needed to identify the environmental factors that
increase both caffeine consumption and sleeping problems, in order
to guide the development of more evidence-based interventions to
improve sleep.
A major strength of our approach, using summary-level data of
very large sample sizes, is that it provides considerable power to
detect small effects, which are likely for complex traits such as caf-
feine consumption and sleep behaviours. There are also limitations
to consider. For the Mendelian randomization analyses we
assumed the caffeine consumption SNPs (Cornelis et al., 2015) to
be associated with caffeine intake in the GWA study of the sleep-
ing variables, but we were not able to test this. The genetic instru-
ment may be weaker if the GWA study of the outcome variable
contains a group of people that do not consume coffee. However,
we have previously shown that the genetic risk score of caffeine
consumption also predicts coffee consumption in the combined
sample of coffee and non-coffee drinkers in UK Biobank (Taylor
et al., 2018). Another limitation is that, for plasma caffeine and
caffeine metabolic rate, we were not able to calculate genetic cor-
relations with sleep behaviours, because of the relatively low sam-
ple size in the GWA studies. In addition, the beta coefficients
resulting from the plasma caffeine/caffeine metabolic rate MR
analyses don’t have interpretable units, given that SNP associa-
tions were constructed from z-scores. We can, however, interpret
the direction of effect and strength of the evidence (p-values) for
these analyses. For sleep behaviours, we relied on self-reported
measures, although self-perceived sleep duration can be influenced
by many other factors and may not fully reflect actual sleep. We
also did not consider other sleep problems, such as sleep-disor-
dered breathing (apnea). Finally, it is important to note that the
relationship between caffeine consumption and sleep is complex
and we may not have been able to address all the complexities
(e.g. timing of caffeine consumption and biological factors related
to caffeine metabolism).
In summary, we did not find clear evidence of causal effects of
caffeine consumption on sleep behaviours, or vice versa. Our find-
ings provide new and relevant insights into the link between caf-
feine consumption and sleep, by showing that a sustained high
consumption of caffeine doesn’t seem to increase the risk of
developing sleep problems. There also doesn’t seem to be a shared
genetic architecture between caffeine intake and sleep. These
results highlight the complexity of interpreting Mendelian random-
ization results for health behaviours such as caffeine consumption
and sleep. Although there are well-known acute effects of caffeine
on alertness this did not translate into strong evidence for causal
effects of a more sustained intake of caffeine on sleep. Research-
ers applying Mendelian randomization should be aware that
genetic variants used as an instrument, or proxy, for an (exposure)
variable, reflect a lifetime exposure to higher or lower levels of
that variable.
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